CA2290974C - Compositions de sertraline solubilisee - Google Patents

Compositions de sertraline solubilisee Download PDF

Info

Publication number
CA2290974C
CA2290974C CA002290974A CA2290974A CA2290974C CA 2290974 C CA2290974 C CA 2290974C CA 002290974 A CA002290974 A CA 002290974A CA 2290974 A CA2290974 A CA 2290974A CA 2290974 C CA2290974 C CA 2290974C
Authority
CA
Canada
Prior art keywords
composition
sertraline
matter
solubilizing agent
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002290974A
Other languages
English (en)
Other versions
CA2290974A1 (fr
Inventor
Dwayne Thomas Friesen
Scott Max Herbig
Ravi Mysore Shanker
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2290974(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CA2290974A1 publication Critical patent/CA2290974A1/fr
Application granted granted Critical
Publication of CA2290974C publication Critical patent/CA2290974C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Compositions comprenant une substance à base de sertraline et un agent de solubilisation qui augmente la solubilité de la sertraline dans des environnements d'utilisation aqueux contenant des ions chlorure.
CA002290974A 1997-07-01 1998-06-15 Compositions de sertraline solubilisee Expired - Fee Related CA2290974C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01
US60/051,413 1997-07-01
PCT/IB1998/000933 WO1999001120A1 (fr) 1997-07-01 1998-06-15 Compositions de sertraline solubilisee

Publications (2)

Publication Number Publication Date
CA2290974A1 CA2290974A1 (fr) 1999-01-14
CA2290974C true CA2290974C (fr) 2004-04-27

Family

ID=21971159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290974A Expired - Fee Related CA2290974C (fr) 1997-07-01 1998-06-15 Compositions de sertraline solubilisee

Country Status (34)

Country Link
EP (1) EP0999829A1 (fr)
JP (1) JP2000514100A (fr)
KR (1) KR100366373B1 (fr)
CN (1) CN1261794A (fr)
AP (1) AP1192A (fr)
AR (3) AR015917A1 (fr)
AU (1) AU742535B2 (fr)
BG (1) BG103918A (fr)
BR (1) BR9810739A (fr)
CA (1) CA2290974C (fr)
CO (1) CO4940495A1 (fr)
DZ (1) DZ2548A1 (fr)
EA (1) EA002481B1 (fr)
HN (1) HN1998000102A (fr)
HR (1) HRP980377A2 (fr)
HU (1) HUP0002236A3 (fr)
ID (1) ID23429A (fr)
IL (1) IL133076A (fr)
IS (1) IS5260A (fr)
MA (1) MA24587A1 (fr)
NO (1) NO996520L (fr)
OA (1) OA11243A (fr)
PA (1) PA8454301A1 (fr)
PE (1) PE97199A1 (fr)
PL (1) PL337804A1 (fr)
SK (1) SK181099A3 (fr)
TN (1) TNSN98124A1 (fr)
TR (1) TR199903297T2 (fr)
TW (1) TW550087B (fr)
UA (1) UA67741C2 (fr)
UY (1) UY25071A1 (fr)
WO (1) WO1999001120A1 (fr)
YU (1) YU68299A (fr)
ZA (1) ZA985708B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3227A1 (fr) 1999-12-23 2001-07-05 Pfizer Prod Inc Compositions pharmaceutiques fournissant des concentrations de medicaments ameliorees
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
CN101631593B (zh) * 2007-03-12 2014-08-13 帝斯曼知识产权资产管理有限公司 化妆品组合物
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
US20130035344A1 (en) * 2009-12-29 2013-02-07 Kowa Co., Ltd. Pharmaceutical composition for oral administration
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736B (zh) * 2022-05-20 2025-03-21 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
IL133076A (en) 2003-12-10
CO4940495A1 (es) 2000-07-24
ZA985708B (en) 2000-01-10
CA2290974A1 (fr) 1999-01-14
PA8454301A1 (es) 2000-09-29
BR9810739A (pt) 2000-09-12
YU68299A (sh) 2002-06-19
ID23429A (id) 2000-04-20
NO996520D0 (no) 1999-12-28
AP1192A (en) 2003-07-23
SK181099A3 (en) 2000-07-11
BG103918A (en) 2000-07-31
EA199900962A1 (ru) 2000-08-28
AR040279A2 (es) 2005-03-23
JP2000514100A (ja) 2000-10-24
AU7544898A (en) 1999-01-25
MA24587A1 (fr) 1998-12-31
AR040280A2 (es) 2005-03-23
UA67741C2 (uk) 2004-07-15
KR20010013365A (fr) 2001-02-26
AR015917A1 (es) 2001-05-30
EA002481B1 (ru) 2002-06-27
OA11243A (en) 2003-07-24
HUP0002236A3 (en) 2003-12-29
KR100366373B1 (ko) 2003-01-14
TNSN98124A1 (fr) 2005-03-15
AU742535B2 (en) 2002-01-03
DZ2548A1 (fr) 2003-02-08
PL337804A1 (en) 2000-09-11
EP0999829A1 (fr) 2000-05-17
NO996520L (no) 2000-02-29
HRP980377A2 (en) 1999-04-30
HN1998000102A (es) 1999-01-08
HUP0002236A2 (hu) 2003-08-28
TW550087B (en) 2003-09-01
AP9801280A0 (en) 1998-06-30
IL133076A0 (en) 2001-03-19
TR199903297T2 (xx) 2000-07-21
WO1999001120A1 (fr) 1999-01-14
UY25071A1 (es) 2000-12-29
IS5260A (is) 1999-11-19
PE97199A1 (es) 1999-10-05
CN1261794A (zh) 2000-08-02

Similar Documents

Publication Publication Date Title
JP3382950B2 (ja) 医薬品用の徐放性マトリックス
US5670171A (en) Liquid-suspension controlled-release pharmaceutical composition
US4772473A (en) Nitrofurantoin dosage form
KR20010012857A (ko) 개선된 약물 전달용 위장체류 방출조절 미소립자
PT1492511E (pt) Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
JP2010163455A (ja) 活性成分放出制御薬物製剤
RU2237480C2 (ru) Непосредственно прессуемая матрица для регулируемого высвобождения однократных ежедневных доз кларитромицина
JP2003513882A (ja) ジバルプロエックスナトリウムの制御放出製剤
PT1492531E (pt) Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas que permite a libertação modificada de amoxicilina
AP1192A (en) Solubilized sertraline compositions.
ES2852899T3 (es) Formulaciones estabilizadas de molindona
HUP0301787A2 (hu) A sertralin késleltetett kibocsátású dózisformái
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
WO2020157730A1 (fr) Composition pharmaceutique à libération contrôlée de sélexipag ou son métabolite actif
JPH069388A (ja) 徐放性塩酸オキシブチニン製剤
JPH0748256A (ja) ニセルゴリンを含有する制御放出性の製薬組成物
PT1618873E (pt) Grânulos para libertação controlada de tamsulosina, que contém alginato.
US20040208926A1 (en) Solubilized sertraline compositions
NZ501250A (en) Solubilized sertraline compositions
CN1319004A (zh) 新的药用制剂
Pagay Use of buffers in matrix capsule formulations
CZ464199A3 (cs) Solubilizované sertralinové kompozice
HUP0200711A2 (hu) Iható gyógyszerészeti szuszpenzió
BR102018016507A2 (pt) Composição líquida de liberação prolongada de guaifenesina

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed